NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance. The cost-effectiveness body said
NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people